Skip to main content

Advertisement

SpringerLink
Log in

Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The purpose of this study is to update a systematic review and meta-analysis comparing low- (2 × 500 or 1 × 1000 mg) and high-dose (2 × 1000 mg) rituximab (RTX) for the treatment of rheumatoid arthritis (RA), considering the recent emergence of new evidence. The systematic literature review searching for randomized controlled trials (RCTs) was updated to November 6, 2014 using the PubMed, EMBASE, Cochrane Library, Web of Science databases, and hand searching. The primary outcomes were the American College of Rheumatology (ACR) criteria for 20 % improvement (ACR20), ACR50, and ACR70 responses and the Disease Activity Score in 28 joints (DAS28) at 24 and 48/52 weeks. The secondary outcomes were change in Health Assessment Questionnaire (HAQ) score, change in the radiographic modified Total Sharp Score (mTSS), levels of immunoglobulin G (IgG), and adverse events. In total, seven RCTs were identified, including two new full publication versions and one abstract of RCTs. There were no significant differences in the primary outcomes and change in HAQ, although the mean change in mTSS was 0.25 units (95 % CI, 0.01 to 0.49; P = 0.04) higher in low-dose group at week 52. Two RCTs did not demonstrate difference between the RTX regimens for maintaining clinical response (obtained initially using high-dose RTX) in anti-TNF-experienced patients. IgG levels were significantly higher (P ≤ 0.02), and first infusion reactions were less frequent in the low-dose group (P = 0.02). Our updated results further support the similar efficacy of both RTX regimens in different subsets of RA patients, demonstrating a better clinical and laboratory safety profile of the low-dose scheme.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bredemeier M, de Oliveira FK, Rocha CM (2014) Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 66:228–35. doi:10.1002/acr.22116

    Article  CAS  Google Scholar 

  2. Vital EM, Md Yusof MY, Emery P (2014) Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al. Arthritis Care Res (Hoboken) 66:1591–3. doi:10.1002/acr.22379

    Article  CAS  Google Scholar 

  3. Bredemeier M (2014) Reply. Arthritis Care Res (Hoboken) 66:1593–6. doi:10.1002/acr.22382

    Article  Google Scholar 

  4. Leandro MJ (2015) Rituximab and other B cell targeted therapies for rheumatoid arthritis. In: Romain PL, Maini RN (Eds), Uptodate, Waltham, MA. http://www.uptodate.com/contents/rituximab-and-other-b-cell-targeted-therapies-for-rheumatoid-arthritis. Accessed on 12 January 2015

  5. Peterfy C, Emery P, Tak PP, Østergaard M, DiCarlo J, Otsa K et al (2014) MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. doi:10.1136/annrheumdis-2014-206015

    Google Scholar 

  6. Mariette X, Rouanet S, Sibilia J, Combe B, Le Loet X, Tebib J et al (2014) Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis 73:1508–14. doi:10.1136/annrheumdis-2013-203480

    Article  CAS  PubMed  Google Scholar 

  7. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. doi:10.1136/bmj.b2535

    Article  PubMed Central  PubMed  Google Scholar 

  8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–24

    Article  CAS  PubMed  Google Scholar 

  9. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727–35

    Article  CAS  PubMed  Google Scholar 

  10. Batticciotto A, Varisco V, Antivalle M, Talotta R, Rigamonti F, Ventura D et al (2013) Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen. Ann Rheum Dis 72(Suppl):877

    Article  Google Scholar 

  11. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, for the DANCER Study Group et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390–1400

    Article  CAS  PubMed  Google Scholar 

  12. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ et al (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69:1629–35. doi:10.1136/ard.2009.119933

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W et al (2012) Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 71:351–7. doi:10.1136/annrheumdis-2011-200170

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G et al (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49:1683–93. doi:10.1093/rheumatology/keq116

    Article  CAS  Google Scholar 

  15. Bredemeier M (2012) Last observation carried forward approach threatens the validity of intent-to-treat analysis in fibromyalgia trials: comment on the article by Arnold et al. Arthritis Rheum 64:2809–10. doi:10.1002/art.34493

    Article  PubMed  Google Scholar 

  16. Leandro MJ, Becerra-Fernandez E (2011) B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 25:535–48. doi:10.1016/j.berh.2011.10.005

    Article  CAS  PubMed  Google Scholar 

  17. Lydersen S (2015) Statistical review: frequently given comments. Ann Rheum Dis 74:323–5. doi:10.1136/annrheumdis-2014-206186

  18. Ma Y, Mazumdar M, Memtsoudis SG (2012) Beyond repeated-measures analysis of variance: advanced statistical methods for the analysis of longitudinal data in anesthesia research. Reg Anesth Pain Méd 37:99–105. doi:10.1097/AAP.0b013e31823ebc74

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Mabel Fernandes Figueiró and Drs. Airton Tetelbom Stein and Sérgio Antônio Sirena on their valuable support.

Disclosures

None.

Author information

Authors and Affiliations

  1. Rheumatology Service, Hospital Nossa Senhora da Conceição − Grupo Hospitalar Conceição, Av. Francisco Trein, 596, Bloco H, sala 2048, Porto Alegre, 91350-200, RS, Brazil

    Markus Bredemeier, Guilherme G. Campos & Fernando K. de Oliveira

Authors
  1. Markus Bredemeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guilherme G. Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fernando K. de Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Bredemeier.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 13725 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bredemeier, M., Campos, G.G. & de Oliveira, F.K. Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis. Clin Rheumatol 34, 1801–1805 (2015). https://doi.org/10.1007/s10067-015-2977-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-2977-z

Keywords

Search

Navigation